(Press-News.org) Barcelona, Spain – Sunday 31 August 2014: Renal denervation seems to be more successful at reducing blood pressure in patients with resistant hypertension when it includes accessory renal arteries, according to research presented at ESC Congress today by Dr Linda Schmiedel from Germany.
Dr Schmiedel said: "More than one billion people worldwide suffer from arterial hypertension, which is defined as blood pressure (BP) greater than 140/90 mmHg. Up to 15% of patients suffer from resistant hypertension (rHTN) and are unable to reduce BP below 140/90 mmHg despite adhering to full doses of an appropriate three drug treatment regimen including diuretics." (1)
She added: "The prevalence and prognosis of rHTN is still unknown, but we do know that cardiovascular risk doubles with each BP increment of 20/10 mmHg. Effective BP treatment is therefore vital, especially in patients with rHTN." (2)
Renal sympathetic denervation (RDN) has been established as an effective treatment for these patients since 2009. It works by decreasing renal sympathetic nerve activity using point-by-point radiofrequency application in the main renal arteries. The procedure is feasible in these arteries because of their size (>20mm long and 4mm in diameter). RDN has shown promising results with BP reductions of 23/11 mmHg in previous studies (3).
But until now, RDN has not been performed in the accessory renal arteries due to their small diameter and the risk of developing a vascular stenosis after catheter ablation.
The aim of the current study was to examine whether complete ablation by performing RDN in accessory renal arteries, in addition to the main renal arteries, would influence blood pressure even more in patients with rHTN. The study included 110 patients with rHTN. At the beginning of the study, mean ambulatory BP was 154±10/85±9 mmHg and patients were taking more than 6 drugs to treat their hypertension.
Six months after RDN, 62 patients were available for follow up and had office BP (OBP) and 24 hour ambulatory BP (ABPM) measurements taken. Overall, the procedure was successful in 42 patients (67%) with a corresponding drop in BP of more than 10 mmHg (figure 1). Of these patients, 34 (54.8%) had complete ablation including the main and accessory arteries.
Dr Schmiedel said: "Our results show that more than half of patients with successful RDN had complete ablation including the main and accessory arteries. Complete ablation seems to be an important factor in achieving success with this procedure."
Out of the 62 patients available at follow up, 12 (19%) had accessory renal arteries that were not completely ablated. The success of RDN was compared between those whose ablation was complete (including main and accessory arteries) compared to those whose ablation
was incomplete (main arteries only). Patients with complete ablation had a greater BP reduction with RDN (18±4/-5±2 mmHg) compared to those whose ablation was incomplete (12±8/3±4 mmHg) but the difference was not significant (p=0.67) (figure 2).
Dr Schmiedel said: "We found that complete ablation produced a noticeable trend for more BP reduction although it was not significant, maybe due to the limited amount of patients. Taking our results together we can conclude that RDN is an effective procedure for treating resistant hypertension but success depends on careful selection and completeness of ablation."
She concluded: "Further investigations focused on the role of accessory renal arteries and the completeness of the RDN procedure are needed to confirm our results."
INFORMATION:
References
(1) Resistant hypertension (rHTN) is defined as office blood pressure greater than 160/90 mmHg, systolic ambulatory blood pressure greater than 135 mmHg and failure to respond to more than 3 appropriate drugs at the highest tolerated doses including diuretics.
(2) Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287(8):1003-1010. (full paper available in the press kit)
(3 )Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903-1909. doi: 10.1016/S0140-6736(10)62039-9. Epub 2010 Nov 17. (full paper available in the press kit)
Notes to editor
Authors: ESC Press Office
Tel: +34 670 521 210 (ESC Spokesperson Coordinator – Tanya Kenny)
Email: press@escardio.org
About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2014
Congress is currently the world's largest international congress in cardiovascular medicine. ESC Congress 2014 takes place 30 August to 3 September at the Fira Gran Via congress centre in Barcelona, Spain.
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2014. The press release has been written by the investigator and edited by the ESC and does not necessarily reflect the opinion of the European Society of Cardiology.
EMBARGO: Sunday 31 August 2014 at 8:30am CEST
SUBMITTED TO A SCIENTIFIC JOURNAL: no
SPONSOR: no
REFERS TO SESSION: Poster session 2: Renal denervation part II http://spo.escardio.org/SessionDetails.aspx?eevtid=69&sessId=14104&subSessId=3539
More information available on ESC Congress 365 after the scientific session: slides and webcast when available (http://congress365.escardio.org/)
Renal denervation more successful when it includes accessory arteries
2014-08-31
ELSE PRESS RELEASES FROM THIS DATE:
Wine only protects against CVD in people who exercise
2014-08-31
Barcelona, Spain – Sunday 31 August 2014: Wine only protects against cardiovascular disease (CVD) in people who exercise, according to results from the In Vino Veritas (IVV) study presented at ESC Congress today by Professor Milos Taborsky from the Czech Republic.
Professor Taborsky said: "This is the first randomised trial comparing the effects of red and white wine on markers of atherosclerosis (1) in people at mild to moderate risk of CVD. We found that moderate wine drinking was only protective in people who exercised. Red and white wine produced the same results."
Evidence ...
Drinking tea reduces non-CV mortality by 24 percent
2014-08-31
Barcelona, Spain – Sunday 31 August 2014: Drinking tea reduces non-cardiovascular mortality by 24%, reveals a study in 131 000 people presented at ESC Congress today by Professor Nicolas Danchin from France.
Professor Danchin said: "If you have to choose between tea or coffee it's probably better to drink tea. Coffee and tea are important components of our way of life. Their effects on cardiovascular (CV) health have been investigated in the past with sometimes divergent results. We investigated the effects of coffee and tea on CV mortality and non-CV mortality in a large ...
New method predicts optimal number and location of AEDs
2014-08-31
Barcelona, Spain – Saturday 30 August 2014: A new method to predict the optimal number and location of automated external defibrillators (AEDs) was presented at ESC Congress today by Dr Benjamin Dahan from France. According to the predictive method, Paris needs 350 AEDs located in public places for optimal prevention of out of hospital cardiac arrest (OHCA).
Dr Dahan said: "Out of hospital cardiac arrest is a major public health issue with an annual incidence ranging between 50 and 100 per 100 000 in the general population in Europe and North America. Because the vast ...
Local anesthetic for TAVI as safe and effective as general anesthetic
2014-08-31
Barcelona, Spain – Sunday 31 August 2014: Local anaesthetic is as safe and effective for transcatheter aortic valve implantation (TAVI) as general anaesthetic, according to results of the FRANCE 2 registry presented at ESC Congress today by Dr Romain Chopard from France.
Dr Chopard said: "Numerous studies have shown that TAVI is a viable treatment alternative for patients with severe symptomatic aortic stenosis who are at very high risk or ineligible for conventional surgical aortic valve replacement. The number of TAVI procedures in France and around the world has increased ...
Retrievable transcatheter aortic valve effective and safe in real world setting
2014-08-31
Barcelona, Spain – Sunday 31 August 2014: A retrievable and repositionable transcatheter aortic valve is effective and safe in a real world setting, according to research presented at ESC Congress 2014 today by Dr Stylianos Pyxaras from Germany. The direct flow medical (DFM) transcatheter aortic valve has unique features that improve operator control and has the potential to improve transcatheter aortic valve implantation (TAVI) outcomes in patients with severe aortic stenosis.
Dr Pyxaras said: "TAVI is well established as a percutaneous treatment option in patients with ...
Batteryless cardiac pacemaker is based on automatic wristwatch
2014-08-31
Barcelona, Spain – Sunday 31 August 2014: A new batteryless cardiac pacemaker based on an automatic wristwatch and powered by heart motion was presented at ESC Congress 2014 today by Adrian Zurbuchen from Switzerland. The prototype device does not require battery replacement.
Mr Zurbuchen, a PhD candidate in the Cardiovascular Engineering Group at ARTORG, University of Bern, Switzerland, said: "Batteries are a limiting factor in today's medical implants. Once they reach a critically low energy level, physicians see themselves forced to replace a correctly functioning ...
AF mortality and morbidity high at 1 year despite good anticoagulant use
2014-08-31
Barcelona, Spain – Sunday 31 August 2014: Mortality and morbidity of atrial fibrillation (AF) patients remains high at one year despite good use of oral anticoagulants, according to the one year follow up of the Atrial Fibrillation General Pilot Registry. The findings were presented for the first time at ESC Congress 2014 today by registry chairperson Professor Gregory Lip (Birmingham, UK).
Professor Lip said: "This is the first contemporary, ESC sponsored registry focused on management practices of European cardiologists conducted since the ESC guidelines on AF were ...
Medication shows mixed results in reducing complications from cardiac surgery
2014-08-30
Administration of colchicine, a plant-based medication commonly used to treat gout, before and after cardiac surgery showed mixed results in reducing potential complications from this type of surgery, but it did increase the risk of gastrointestinal adverse effects, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology Congress.
Common complications after cardiac surgery include postpericardiotomy syndrome (the occurrence of the symptoms of pericarditis, including chest ...
Transvenous lead extraction clinically successful in 98 percent of cases
2014-08-30
Barcelona, Spain – Saturday 30 August 2014: Transvenous lead extraction (TLE) is clinically successful in more than 98% of cases according to data from the European Lead Extraction ConTRolled (ELECTRa) registry presented for the first time today at ESC Congress 2014 by Dr Maria Grazia Bongiorni, chair of the registry's executive committee.
Dr Bongiorni said: "The number of cardiac implantable electronic devices (CIED) implant procedures has grown in recent years. Despite advances in technology the number of complications has increased and leads are often the cause. TLE ...
First multidisciplinary recommendations on management of arrhythmias in ACS patients
2014-08-30
Barcelona, Spain – Saturday 30 August 2014: The first multidisciplinary recommendations on the management of arrhythmias in patients with acute coronary syndromes (ACS) are published today in EP Europace.
The position paper was written jointly by the European Heart Rhythm Association (EHRA), the Acute Cardiovascular Care Association (ACCA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), all of the ESC.
Professor Bulent Gorenek (Turkey), chairperson of the task force, said: "Sudden cardiac death is the leading cause of death in Europe, ...